1 results match your criteria: "Institute of Molecular and Cellular Biology of Cancer (IBMCC)-CSIC[Affiliation]"
Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer.
NPJ Precis Oncol
August 2021
Institute of Molecular and Cellular Biology of Cancer (IBMCC)-CSIC, Salamanca, Spain.
Article Synopsis
- Lung cancer remains the most common and deadly cancer, prompting research into its biological mechanisms to develop new treatments.
- Previous research indicated that the activation of the MEK5/ERK5 signaling pathway plays a significant role in lung adenocarcinoma development.
- Studies showed that high levels of MEK5/ERK5 are linked to worse outcomes in lung cancer patients, and targeting this pathway can effectively inhibit tumor growth and enhance the efficacy of existing treatments.